Eli Lilly Q2 2016 results surpass estimates

July 27, 2016
Research and Development, Sales and Marketing Eli Lilly, financial report

Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results.  The …

Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals

July 27, 2016
Research and Development phase III, prostate cancer, tokai pharmaceuticals

Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …

GSK announces significant post-Brexit UK investment

July 27, 2016
Manufacturing and Production, Research and Development GSK, UK, brexit, investment

GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …

New drugs to utilise DNA damage response to kill cancer cells

July 26, 2016
Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …

Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial

July 26, 2016
Research and Development Celgene, Revlimid, lymphoma

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …

BMS names Fouad Namouni as new oncology development head

July 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …

Gilead lowers full-year guidance as sales and profits down in Q2

July 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results

Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …

IBS-D treatment Truberzi receives positive opinion from CHMP

July 26, 2016
Manufacturing and Production, Sales and Marketing Allergan, EU, Truberzi, diarrhoea. CHMP, irritable bowel syndrome

Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …

Darzalex receives breakthrough designation in multiple myeloma from FDA

July 26, 2016
Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …

AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo

July 26, 2016
Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t

AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …

CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment

July 25, 2016
Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis

Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …

The ethical battle for the future of pharma

July 25, 2016
Drug pricing, ethics in pharma

A battle is raging for the soul of the pharma industry and the stakes are high. Those companies seeking to …

MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use

July 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza

Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …

Flawed studies at Semler Research Centre calls for suspension of medicines, EMA recommends

July 25, 2016
Manufacturing and Production, Sales and Marketing EMA, Novartis, Teva, manufacturing, semler

Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …

400 current and former employees join sexual discrimination lawsuit against MSD

July 25, 2016
Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …

AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C

AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …

EU recommends PrEP in Gilead’s HIV prevention treatment

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …

Shire receives positive EU opinion for pancreatic cancer drug

July 25, 2016
Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …

EMA recommends two new treatments for advanced kidney cancer

July 22, 2016
Research and Development, Sales and Marketing EMA, Eisai, renal cell carcinoma

The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …

The Gateway to Local Adoption Series

Latest content